Use of Streptococcus salivarius K12 to reduce the incidence of pharyngo-tonsillitis and acute otitis media in children: a retrospective analysis in not-recurrent pediatric subjects

Pierro, Francesco Di; Risso, P.; Poggi, Elena; Timitilli, Anna; Bolloli, Sara; Bruno, Maurizio; Caneva, Egidio; Campus, Riccardo; Giannattasio, A.

doi:10.23736/s0026-4946.18.05182-4

Cited by 26 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date, some of the best documented commercially available probiotics targeting URT and oral health are Streptococcus salivarius strains K12, M18, and 24SMB and S. oralis 89a ( 30 – 41 ). S. salivarius K12 may reduce AOM by up to 71.5% and was also found to reduce adenoid and tonsil hypertrophy and cause a clearing of middle ear effusion ( 32 – 36 ), although one study observed no difference in AOM episodes compared to untreated controls ( 37 ). A nasal spray combining S. salivarius 24SMB and S. oralis 89a was found, by dedicated quantitative PCR (qPCR), to reduce the number and severity of AOM episodes in otitis-prone children, especially when S. salivarius 24SMB colonized the respiratory tract ( 38 – 40 ), and to reduce adenoid hypertrophy and middle ear effusion in children with chronic OME, with significant reduction in need for surgery from 90.9% of the children in the control group to 27.3% in the treatment group ( n = 22 in each group) ( 41 ).…”

Section: Introductionmentioning

confidence: 99%

Case-Control Microbiome Study of Chronic Otitis Media with Effusion in Children Points at Streptococcus salivarius as a Pathobiont-Inhibiting Species

et al. 2021

View full text Add to dashboard Cite

Chronic otitis media with effusion (OME) has been associated with a shift in microbiome composition and microbial interaction in the upper respiratory tract (URT). While most studies have focused on potential pathogens, this study aimed to find bacteria that could be protective against OME through a case-control microbiome study and characterization of isolates from healthy subjects. The URT and ear microbiome profiles of 70 chronic OME patients and 53 controls were compared by 16S rRNA amplicon sequencing. Haemophilus influenzae was the most frequent classic middle ear pathobiont. However, other taxa, especially Alloiococcus otitis, were also frequently detected in the ear canal of OME patients. Streptococci of the salivarius group and Acinetobacter lwoffii were more abundant in the nasopharynx of healthy controls than in OME patients. In addition to the microbiome analysis, 142 taxa were isolated from healthy individuals, and 79 isolates of 13 different Streptococcus species were tested for their pathobiont-inhibiting potential. Of these, Streptococcus salivarius isolates showed a superior capacity to inhibit the growth of H. influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, A. otitis, and Corynebacterium otitidis. S. salivarius strains thus show potential as a probiotic for prevention or treatment of OME based on their overrepresentation in the healthy nasopharynx and their ability to inhibit the growth of respiratory pathobionts. (This study has been registered at ClinicalTrials.gov under registration no. NCT03109496.) IMPORTANCE The majority of probiotics marketed today target gastrointestinal health. This study searched for bacteria native to the human upper respiratory tract, with a beneficial potential for respiratory and middle ear health. Comparison of the microbiomes of children with chronic otitis media with effusion (OME) and of healthy controls identified Streptococcus salivarius as a health-associated and prevalent inhabitant of the human nasopharynx. However, beneficial potential should be assessed at strain level. Here, we also isolated specific S. salivarius strains from the healthy individuals in our study. These isolates showed a beneficial safety profile and efficacy potential to inhibit OME pathogens in vitro. These properties will now have to be evaluated and confirmed in human clinical studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Case-Control Microbiome Study of Chronic Otitis Media with Effusion in Children Points at Streptococcus salivarius as a Pathobiont-Inhibiting Species

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Certain commensal streptococci encompassing representatives of S. salivarius, Streptococcus vestibularis and S. cristatus have been described in previous studies as immunosuppressive in a range of cell types in vitro , and S. salivarius inhibits inflammation in an animal model [ 4, 13–17 ], as well as in humans in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes , and recurrent acute otitis media [ 28 ]. The roles of such immunosuppressive organisms in host-microbe homeostasis in vivo in the mouth is not known; however, Twetman et al demonstrated that the use of chewing gum containing immunosuppressive probiotic lactobacilli was associated with transient reductions in CXCL8 secretion into gingival crevicular fluid [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

Immunomodulatory streptococci that inhibit CXCL8 secretion and NFκB activation are common members of the oral microbiota

Myers

Meade

et al. 2021

Journal of Medical Microbiology

View full text Add to dashboard Cite

Introduction. Oral tissues are generally homeostatic despite exposure to many potential inflammatory agents including the resident microbiota. This requires the balancing of inflammation by regulatory mechanisms and/or anti-inflammatory commensal bacteria. Thus, the levels of anti-inflammatory commensal bacteria in resident populations may be critical in maintaining this homeostatic balance. Hypothesis/Gap Statement. The incidence of immunosuppressive streptococci in the oral cavity is not well established. Determining the proportion of these organisms and the mechanisms involved may help to understand host-microbe homeostasis and inform development of probiotics or prebiotics in the maintenance of oral health. Aim. To determine the incidence and potential modes of action of immunosuppressive capacity in resident oral streptococci. Methodology. Supragingival plaque was collected from five healthy participants and supragingival and subgingival plaque from five with gingivitis. Twenty streptococci from each sample were co-cultured with epithelial cells±flagellin or LL-37. CXCL8 secretion was detected by ELISA, induction of cytotoxicity in human epithelial cells by lactate dehydrogenase release and NFκB-activation using a reporter cell line. Bacterial identification was achieved through partial 16S rRNA gene sequencing and next-generation sequencing. Results. CXCL8 secretion was inhibited by 94/300 isolates. Immunosuppressive isolates were detected in supragingival plaque from healthy (4/5) and gingivitis (4/5) samples, and in 2/5 subgingival (gingivitis) plaque samples. Most were Streptococcus mitis/oralis. Seventeen representative immunosuppressive isolates all inhibited NFκB activation. The immunosuppressive mechanism was strain specific, often mediated by ultra-violet light-labile factors, whilst bacterial viability was essential in certain species. Conclusion. Many streptococci isolated from plaque suppressed epithelial cell CXCL8 secretion, via inhibition of NFκB. This phenomenon may play an important role in oral host-microbe homeostasis.

show abstract

“…SsK12 не только проявляет выраженную активность против патогенных микробов, но и имеет высокий профиль безопасности [3,4]. Во время орального приема он колонизирует полость рта и носоглотки [5] и, конкурируя с патогенной микрофлорой, способен там сохраняться в течение месяца после приема последней дозы [6]. С учетом спектра действия, использование SsK12 демонстрирует положительный эффект в профилактике рекуррентных заболеваний дыхательных путей, слизистой полости рта [1,7,8], а также отитов у детей [9].…”

Section: Methodsunclassified

Пути Оптимизации Лечения Детей Сзаболеваниями Дыхательных Путей И Лор-Органов

Крючко¹,

Ткаченко²,

Несина³

et al. 2021

Педиатрия. Восточная Европа

View full text Add to dashboard Cite

Введение. Острые респираторные заболевания занимают одно из ведущих мест среди инфекционных болезней детского возраста. Сегодня большое количество исследований проводится в направлении усовершенствования методов лечения инфекционной патологии, в частности изучения эффективности и расширения возможностей применения в практической медицине бактериоцинов, основным источником которых являются грамположительные бактерии. Бактериоцины представляют собой антимикробные пептиды, обладающие широким противомикробным спектром действия. В частности, Streptococcus salivarius K12 является микроорганизмом, продуцирующим бактериоцины I класса (лантибиотики), способные интенсивно подавлять рост Streptococcus pyogenes, Streptococcus pneumonia, Haemophilus influenza и Moraxella catarrhalis, которые являются основными этиологическими факторами респираторных инфекций у детей. Цель. Изучение эффективности и безопасности применения препарата Бактоблис® (саше) на основе Streptococcus salivarius K12 и витамина D3 в комплексном лечении острых тонзиллитов, риносинуситов, стоматитов и отитов у детей. Материалы и методы. Проведено открытое нерандомизированное клиническое исследование при участии 55 пациентов в возрасте от 3 до 7 лет с острой респираторной инфекцией верхних дыхательных путей (риносинуситы, тонзиллиты), воспалением слизистой полости рта исреднего уха. В основную группу вошли 35 детей, которые в течение 10 дней в комплексном лечении получали Бактоблис® на основе Streptococcus salivarius K12 (SsK12) в форме саше. Группу контроля составили 20 детей, которым назначали стандартную терапию без респираторного пробиотика (SsK12). Оценка эффективности лечения проводилась на основании изучения динамики регресса клинической симптоматики в ходе 10-дневного курсового применения. Результаты. Полученные результаты четко показывают эффективность комплексного лечения детей основной группы - достоверное улучшение течения острого риносинусита, тонзиллита и стоматита (р<0,01) и более быстрый регресс клинической симптоматики. Полученный эффект в виде уменьшения продолжительности заболевания в среднем на 2 дня, скорее всего, реализуется за счет колонизации слизистой ротовой полости и носоглотки штаммом Streptococcus salivarius K12 и вытеснения патогенной микрофлоры. Заключение. Бактоблис® в форме саше способен достоверно уменьшить длительность острой респираторной патологии, а также частоту применения антибактериальных препаратов у данной категории пациентов, что расширяет возможности использования Streptococcus salivarius K12 в комплексном лечении заболеваний дыхательных путей и лор-органов у детей в периоде обострения. Introduction. Acute respiratory diseases occupy one of the leading places among infectious diseases of childhood. Today, a large number of studies is carried out in the direction of studying the effectiveness and expanding the possibilities of using probiotics in practical medicine, particularly lantibiotics. In particular, Streptococcus salivarius K12 is a microorganism that produces the class I bacteriocins (lantibiotics) that can intensely inhibit the growth of Streptococcus pyogenes, Streptococcus pneumonia, Haemophilus influenza, and Moraxella catarrhalis that are significant etiological factors of respiratory infections in children. Purpose. To study the efficacy and safety of using the drug Bactoblis® (sachet) based on Streptococcus salivarius K12 and vitamin D in the complex treatment of acute upper respiratory tract diseases in children. Materials and methods. An open non-randomized clinical study was conducted with the participation of 55 patients aged from 3 to 7 years with acute respiratory infections of the upper respiratory tract (rhinosinusitis, tonsillitis, stomatitis, otitis media). The main group included 35 children, who received SsK12 in complex treatment for 10 days. The control group consisted of 20 children, who were prescribed the standard therapy without probiotic. The children of the main group, along with the main therapy, received Bactoblis® in the form of sachet based on Streptococcus salivarius K12. Evaluation of the effectiveness was carried out on the base of studying the dynamics of regression of clinical symptoms during a 10-day course of use. Results. The obtained results clearly show the effectiveness of complex treatment of children in the main group, which is characterized by a significant improvement of the course of sinusitis, tonsillitis and stomatitis (p<0.01) and is manifested by a more rapid regression of clinical symptoms. The resulting effect in the form of decrease of duration of the disease by 2 days on average is implemented due to colonization of the oral mucosa and nasopharynx with the Streptococcus salivarius K12 strain and displacement of pathogenic microflora. Conclusion. Bactoblis® in the form of sachet is able to reliably reduce the duration of acute respiratory pathology, as well as the frequency of use of antibacterial drugs in this category of patients, which expands the possibility of using Streptococcus salivarius K12 in the complex treatment of diseases of the respiratory tract in children during exacerbation.

show abstract

Use of Streptococcus salivarius K12 to reduce the incidence of pharyngo-tonsillitis and acute otitis media in children: a retrospective analysis in not-recurrent pediatric subjects

Cited by 26 publications

References 0 publications

Case-Control Microbiome Study of Chronic Otitis Media with Effusion in Children Points at Streptococcus salivarius as a Pathobiont-Inhibiting Species

Case-Control Microbiome Study of Chronic Otitis Media with Effusion in Children Points at Streptococcus salivarius as a Pathobiont-Inhibiting Species

Immunomodulatory streptococci that inhibit CXCL8 secretion and NFκB activation are common members of the oral microbiota

Пути Оптимизации Лечения Детей Сзаболеваниями Дыхательных Путей И Лор-Органов

Contact Info

Product

Resources

About